
Neurology® Podcast Establishing Potosi Virus as a Human Pathogen - Part 2
Nov 12, 2026
Justin Abbatemarco, a neurologist and clinician-researcher specializing in autoimmune neurology and neuroinfections, discusses infection risks during immunosuppressive therapy. Topics include IVIG for severe viral infections, vaccination during B-cell therapy, seasonal exposure, unexplained cognitive decline, Good syndrome, advanced infection-risk assessment, and measles immunity before treatment.
AI Snips
Chapters
Transcript
Episode notes
Consider IVIG Carefully In Severe Viral Infections
- Consider IVIG with allergy and immunology when B-cell-depleted patients have low immunoglobulin levels.
- Preserve serum and CSF samples first because IVIG can cloud diagnostic results; evidence remains limited.
IVIG May Be A Theoretical Rescue Option
- IVIG for infections such as West Nile may provide donor-derived antibodies, but clinicians should present it as theoretical rescue treatment.
- Stacey Clardy describes it as a multidisciplinary decision supported mainly by low-quality evidence and hope.
Reframe Flu Vaccination For B-Cell Patients
- Do not give live vaccines after starting B-cell therapy, and explain that vaccination mainly reduces severity rather than preventing infection.
- Reassess risk because immunosuppression changes patients’ baseline vulnerability, even if they rarely had influenza before.
